A faecal-transplant therapy called Rebyota has been approved by the US Food and Drug Administration. A single dose can prevent a type of recurrent infection in the gut. Between 15,000 adults and 30,000 people in the US each year die each year due to a recurrent infection. The treatment uses human stools donated to prevent recurrent Clostridioides infections (CDI) The drug was developed by Swiss company Ferring by Swiss Pharmaceutical company Ferlinglingling Pharmaceuticals. It is the first approved product approved for use by US FDA (FDA) and is now available in the U.S. market for $1,000,000. The drug has been developed by the Swiss Pharmaceuticals and is available in Europe and Australia. . . .
Read more at www.newscientist.com
